SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-23-001575
Filing Date
2023-08-14
Accepted
2023-08-14 15:52:14
Documents
48
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymox_6k.htm   iXBRL 6-K 44823
2 EX-99.1 nymox_ex991.htm   iXBRL EX-99.1 497585
3 EX-99.2 nymox_ex992.htm EX-99.2 13459
  Complete submission text file 0001640334-23-001575.txt   2346765

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nymox-20230630.xsd EX-101.SCH 44583
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymox-20230630_lab.xml EX-101.LAB 149887
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymox-20230630_cal.xml EX-101.CAL 33007
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymox-20230630_pre.xml EX-101.PRE 122351
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymox-20230630_def.xml EX-101.DEF 58801
42 EXTRACTED XBRL INSTANCE DOCUMENT nymox_6k_htm.xml XML 372822
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 231169361
SIC: 2835 In Vitro & In Vivo Diagnostic Substances